Adoption of Abiraterone and Enzalutamide by Urologists

OBJECTIVE: To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. METHODS: Using the Medicare Par...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Urology
Main Authors: Caram, Megan E.V., Kaufman, Samuel R., Modi, Parth K., Herrel, Lindsey, Oerline, Mary, Ross, Ryan, Skolarus, Ted A., Hollenbeck, Brent K., Shahinian, Vahakn
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6711811/
https://ncbi.nlm.nih.gov/pubmed/31136769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urology.2019.05.012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados